Development of Aptamer-based assay methods (including aptamers generation, aptamer affinity screening and aptamer based assay design e.g. aptasensor).
LC/MS drug characterization and metabolomics.
Organometallic anticancer analysis using high-resolution continuum-source atomic absorption spectrometry (HR-CS-AAS).
Fast HPLC method development and validation using monolithic columns (applying high flow rates, flow programming and column-to-column coupling) and/or using fused core columns.
Monolithic silica epoxy columns derivatization for the immobilization of new chiral selectors or affinity interactions.
Method development and validation using HILIC HPLC columns for polar solutes.
Bio-analysis of drugs from blood and/or urine samples after proper sample preparation using LC with fluorescence detection or using capillary electrophoresis.
Bioanalysis with direct serum injection (dilute and shoot) using shielded hydrophobic phase (Hisep HPLC column).
Enantiomeric drug separation and enantiomeric impurity determination (down to a concentration level of 0.1% or less relative to the main enantiomer) for quality control of chiral drugs using HPLC with chiral-based stationary phase (e.g. vancomycin-based HPLC column) or CE with different types of native and derivatized cyclodextrins and applying normal and reversed polarity modes.